Macomics and Ono Pharmaceutical partner to discover and develop macrophage-targeting antibody therapy for the treatment of cancer

Worldwide drug discovery collaboration agreement with Ono to develop new antibody drugs against a novel macrophage target of interest in immuno-oncology

Brainomix receives FDA clearance for its flagship stroke AI imaging software

The Oxford, UK headquartered company, long established as a market leader in Europe and a pioneer in the development of innovative stroke AI solutions, is now poised to take its transformative technology to US stroke centers

Unlocking the power of Virtual Reality to overcome anxiety and phobias

XR Therapeutics is a start-up company, spun out of Newcastle University, helping people to overcome their phobias or anxiety using Virtual Reality technology. We spoke with Penny Day, Head of Operations, about the role of virtual reality in mental health treatment, and how XR is making waves in this space.

CEO Update | 20 March 2023

The Budget last week had major wins for BIA members including changes to R&D tax credits rates for loss-making SMEs. Read our press release and Martin’s analysis blog. This is a major, major win for a BIA campaign and wouldn’t have happened without member engagement and perseverance. Many thanks to all who helped – this non dilutive government co-investment will make all the difference as you crowd in private sector investment.

Spring Budget analysis: Chancellor delivers a boost for biotech

The Chancellor has revealed an enhanced R&D tax relief rate for “R&D intensive SMEs” and delayed restrictions for claims on overseas activity following the BIA’s campaign. In a Spring Budget designed to show he has a steady hand on the tiller and a plan to put wind in the UK’s sails, the Chancellor’s Spring Budget was packed full of announcements for the life sciences sector, including a funding boost for the medicines regulator and investment zones around the UK.

You can't beat a beta-defensin

Meet Dr Jimi Wills. With over 20 year of experience as an academic scientist, working with diverse partners in wet and dry labs across sector, Jimi is now a Senior Software Engineer at Firefinch Software. Firefinch are a group of experienced software engineers and problem solvers, with a combined 50+ years in biotechnology, engineering and manufacturing. Jimi was part of a multidisciplinary collaboration that published a paper in Nature last month, evaluating the role of Human Beta Defensin 2 in the treatment of atopic dermatitis. Learn about the findings in his blog!

CF AMR Syndicate launches £3 million Collaborative Discovery Programme

Funding new antimicrobials to treat lung infections in people with Cystic Fibrosis

Sustaining skills to supercharge the UK life sciences sector

Medicines Discovery Catapult celebrates British Science Week 2023

Chancellor gives boost to medical innovation and life sciences industry in Spring Budget

The UK’s Chancellor, Jeremy Hunt, has announced a special higher R&D tax relief rate for the UK’s most innovative businesses in his Spring Budget today (15 March). The UK’s trade association for innovative life sciences and biotech, the UK BioIndustry Association (BIA), has warmly welcomed the announcement.

Coulter Partners places Vice President of Intellectual Property at Amphista Therapeutics

Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health and Tech, recently partnered with Amphista Therapeutics to further strengthen their team in Cambridge with the appointment of Dr Victoria Lovatt as Vice President of Intellectual Property.